Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR Engineered Autologous T Cells and Decitabine in Ovarian Cancer
NCT03017131Phase 1Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NY-ESO-1 TCR-T cells in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events. Started Dec 2017; status: active, not recruiting.
02
Drugs
NY-ESO-1 TCR-T cells
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03017131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017131.